Studies presented at Obesity Week 2025 validate the testâs ability to predict weight-loss response to GLP-1 drugs like semaglutide, including in diverse patient populations and post-bariatric surgery patients.
In conjunction with Obesity Care Week, a national survey from Phenomix Sciences among medication-experienced patients found that GLP-1 outcomes, tolerability, and downstream care needs vary widely, reinforcing the need for more individualized obesity care.
Findings presented at the 2026 Pacific Symposium on Biocomputing demonstrate feasibility of using genetic and behavioral data to assess Emotional Hunger risk in obesity.
Published in Cell Metabolism, the Phenomix and Mayo Clinic research shows the MyPhenomeTM test can help providers guide obesity treatment by matching patients to GLP-1s or phentermine/topiramate based on their unique biology.
A novel gene risk score, informed by machine learning, predicted weight-loss outcomes after Roux-en-Y gastric bypass (RYGB) surgery, a new analysis showed.
Research presented at Digestive Disease Week 2025 is the first to show that the MyPhenome test can identify patients at risk for weight regain and those most likely to benefit from bariatric procedures.
The extensive body of research from Mayo Clinic emphasizes major advancements in obesity, including prediction of GLP-1 side effects, a new obesity sub-phenotype, and insights into personalized bariatric and endoscopic procedures.
